66 results about "Human breast" patented technology

The application belongs to the technical field of medicine, and relates to N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compounds and a preparation method and application thereof. The preparation method of the compound is as follows: taking o-aminobenzoic acid as a starting material, performing substitution reaction, condensation reaction, alkylation reaction and hydrolysis reaction to generate a key intermediate acridone acetic acid, and finally performing condensation reaction on the acridone acetic acid and substituted pyrimidine in the presence of TCFH and NMI condensing agents to obtain the target compound. The preparation method of the N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compound provided in the application is simple and feasible, and good results are shown in in-vitro anti-tumor activity tests, and the compound has excellent anti-proliferation ability on human breast cancer cells BT-549 and MDA-MB-231 in particular.

The invention belongs to the technical field of pharmacy, and particularly relates to application of polycyclic alkaloid in preparation of an anti-breast cancer drug, and the polycyclic alkaloid is 1, 2a, 7-trimethyl-5-tosyl-1, 2, 2a, 3, 4, 5-hexahydropyrrolo [4, 3, 2-de] quinoline. The polycyclic alkaloid compound is applied to preparation of anti-breast cancer drugs, the effect of inhibiting growth of breast cancer cells is remarkable, and the efficacy of the polycyclic alkaloid compound is far better than that of a positive drug ML162 aiming at EC50 (mu M) + / -S.D = 9.04 + / -0.37 of HCC1937 human breast cancer cells.

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

The invention discloses a breast pump. The breast pump comprises at least one detection module, a processing module, a breast pumping shield, a breast pumping channel part and a negative pressure mechanism, the breast suction shield comprises a flange used for being attached to a human breast body. The breast sucking channel part is in sealed connection with the breast sucking shield and is used for accommodating a nipple and allowing milk to flow; the negative pressure mechanism is used for directly or indirectly applying negative pressure into the breast pumping channel part; the detection module is used for detecting brightness change caused by movement of a target object in the breast pumping shield or the breast pumping channel part and generating detection data, and the processing module is used for determining breast pumping related parameters according to the detection data. The detection module generates the detection data by detecting the brightness change caused by the movement of the target object, and the generated detection data is less influenced by the individual difference of the mother, so that the measurement interference caused by the difference of different individuals can be effectively avoided, and the finally determined breast pumping related parameters can be more accurate.

Disclosed in the present invention are a PARP1 / CDK6 dual-target inhibitor, and a preparation method therefor and the use thereof. The PARP1 / CDK6 dual-target inhibitor is a compound having a structure represented by formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein L is selected from or , and R is selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, sulfhydryl, cyano, nitro, methoxy, a C1-C8 alkyl, or a C3-C8 cycloalkyl. The PARP1 / CDK6 dual-target inhibitor of the present invention exhibits good effects against human breast cancer cells, and maintains a good in vitro enzyme inhibitory activity against CDK6 and PARP1. Disclosed in the present invention is the use of a CDK6 / BRD4 dual-target inhibitor in the preparation of a drug for treating PARP1 / CDK6-mediated diseases. Disclosed in the present invention is the use of a PARP1 / CDK6 dual-target inhibitor in the preparation of a drug for treating or preventing triple-negative breast cancer.

The invention discloses an antibody or an antigen binding fragment specifically binding to trop2. The antibody or the antigen binding fragment comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequence of the HCDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO.2, the amino acid sequence of the HCDR3 is as shown in SEQ ID NO.3, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO.4, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO.6. The expression condition of trop2 in human breast cancer and pancreatic cancer cell membrane tissue samples can be detected through an immunohistochemical method, and the adjoint diagnostic kit for the humanized trop2 antibody coupling medicine has the advantages of assisting in precise medication and avoiding invalid treatment.

This utility model discloses a two-piece bra cup with longitudinal segmentation and a bra having the cup, including a first longitudinal piece and a second longitudinal piece, wherein the thickness of the first longitudinal piece is less than the thickness of the second longitudinal piece; the first longitudinal piece is located on the side of the cup near the center gore, and the second longitudinal piece is located on the side of the cup away from the center gore; the edge of the second longitudinal piece near the first longitudinal piece is a smooth curve that rises towards the first longitudinal piece, and this edge extends from the bottom of the cup to the ear area; the first longitudinal piece covers the nipple area, and the edges of the first and second longitudinal pieces close to each other are spliced ​​and fixed to make the cup have a three-dimensional bowl-shaped structure corresponding to the curvature of the human breast. The bra cup provided by this utility model has the advantages of good lifting effect, strong side push and gathering, leak prevention, breathability and comfort, and making it appear smaller when worn.

The invention discloses an automatic human mammary gland examination system based on a large language model combined with a six-axis robot, which can accurately understand a natural language instruction of a clinician by deeply fusing the natural language processing capability of the large language model, the high-precision motion control of the robot and an advanced medical image processing algorithm. A scanning path is automatically planned and executed, a two-dimensional ultrasonic image sequence is collected, a three-dimensional mammary gland model is reconstructed, the model is analyzed through an intelligent algorithm, and a structured clinical diagnosis report is automatically generated, so that full-chain automation of mammary gland ultrasonic scanning from intention understanding to report generation is realized; the standardization degree, efficiency and diagnosis consistency of mammary gland ultrasonic examination are remarkably improved, a reliable automatic solution is provided for early screening and precise diagnosis of mammary gland diseases, and the technical difficulties that in the prior art, due to manual operation, efficiency is low, repeatability is poor, and results depend on experience of operators are solved.

A method of treating cancer cells includes contacting the cancer cells with a CoO / CaSiO3@g-C3N4 nanocomposite material. The CoO / CaSiO3@g-C3N4 nanocomposite material includes hexagonal metal oxide nanoparticles comprising a CoO phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets. The hexagonal metal oxide nanoparticles have an average particle diameter in a range from 340 to 440 nm. The CoO / CaSiO3@g-C3N4 nanocomposite material has a percent inhibition for Human Breast Carcinoma (MCF-7) cells at least 55% inhibition in an in-vitro cellular viability assay.

The invention discloses a thiosemicarbazone compound containing a naphthyl structure as well as a preparation method and application of the thiosemicarbazone compound. The thiosemicarbazone compound has biological activity on human breast cancer cells. The anti-tumor activity of the compound is verified through in-vitro experiments, including an inhibition effect experiment of the compound on proliferation of human breast cancer cells, an influence experiment on oxidative stress level of the breast cancer cells, an influence experiment on mitochondrial membrane potential of the breast cancer cells and an experiment for inducing apoptosis of the breast cancer cells. The thiosemicarbazone compound containing the naphthyl structure has remarkable anti-tumor activity, can effectively inhibit proliferation of human breast cancer cells, can remarkably improve the oxidative stress level of the breast cancer cells in a concentration-dependent mode, and has a close correlation between the regulation effect on the mitochondrial membrane potential of the breast cancer cells and the treatment concentration; the compound can effectively induce apoptosis of breast cancer cells, has excellent anti-breast cancer activity, and provides important candidate compounds and theoretical basis for research and development of novel anti-tumor drugs.

The present application provides a kind of bivalent platinum complex with anastrozole as ligand and its use, the structure of the bivalent platinum complex is as shown in (I).The bivalent platinum complex described in the present application has good antitumor activity.In the present method, anastrozole is reacted with potassium chloroplatinite in an organic solvent to obtain a bivalent platinum complex with anastrozole as ligand, and is applied to the antiproliferation of human breast cancer cells, showing excellent antitumor activity.

The invention discloses a breast pump. The breast pump comprises at least one detection module, a processing module, a breast pumping shield, a breast pumping channel part, a negative pressure mechanism and a milk storage container, the breast suction shield comprises a flange used for being attached to the breast of the human body. The breast sucking channel part is in sealed connection with the breast sucking shield and is used for accommodating a nipple and allowing milk to flow; the negative pressure mechanism is used for directly or indirectly applying negative pressure into the milk sucking channel part, and milk flows into the milk storage container through the milk sucking channel part; the detection module is used for detecting brightness change in a milk flowing path and generating detection data; the processing module is used for determining milk related parameters according to the detection data. The brightness change in a milk flowing path can be detected, and detection data can be generated; and the milk related parameters are determined according to the detection data, so that the accuracy of detecting the milk related parameters is improved.

The invention relates to the technical field of anti-tumor pharmacy. Specifically, the invention relates to an anti-tumor activity application of a compound with a structure as shown in a formula I. In-vitro MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) antitumor activity evaluation finds that the compound shown in the formula I has a remarkable inhibiting effect on the growth of human colorectal cancer HCT116 and human breast cancer cells MCF-7. The anti-tumor activity of the compound with the structure shown in the formula I is disclosed for the first time, and the compound can be used for preparing medicines for resisting colorectal cancer and other tumors and has good development and application prospects. .

A sesquiterpene acyl glycoside in rhizoma artemisiae japonicae and preparation method and application thereof. The present application belongs to the technical field of medicine, and relates to extraction and separation of a sesquiterpene acyl glycoside compound rhizoma artemisiae japonicae cembranoid I from rhizome of rhizoma artemisiae japonicae by using macroporous resin, silica gel and preparation chromatography and the like, and the preparation method is simple and easy to implement. 23 H 38 O 10 In vitro human cancer cell inhibition activity research shows that the compound has anticancer activity, including obvious inhibition on human colon cancer cells HT-29 and human breast cancer MCF-7 cells, and is expected to be developed into a new anticancer drug.

The invention discloses a polypeptide degradation agent targeting ANP32B protein as well as a preparation method and application of the polypeptide degradation agent, and belongs to the technical field of tumor targeted therapy. The polypeptide degradation agent targeting the ANP32B protein is obtained by modifying an ANP32B protein targeting binding ligand (the sequence of the ANP32B protein targeting binding ligand is shown as SEQ ID NO.1-SEQ ID NO.4 in a table 1); wherein R6 (RRRRRRR) is a cationic cell membrane penetrating peptide, and is connected with a polypeptide ligand (IAP (OH) YI) of the E3 ubiquitin ligase VHL through Linker (Acp). Experiments prove that the polypeptide degradation agent targeting the ANP32B protein has the capability of remarkably inhibiting the activity of breast cancer cells MDA-MB-231, can degrade target proteins in the cells and influence the cell cycles of the breast cancer cells MDA-MB-231, can be used for preparing anti-tumor drugs, has a good application prospect in preparation of drugs targeting human breast cancer cells, and has a wide application prospect in preparation of drugs targeting human breast cancer cells. The polypeptide can be used in another important field of polypeptide PROTAC drug development.

The invention discloses a 7-site amino-acid ester-cholesteric derivative, the chemical structure of which is shown in the following formula: wherein the 7-site amino-acid ester-cholesteric derivative has an inhibition effect on human breast cancer cells, human ovarian cancer cells, human breast duct cancer cells and human cervical cancer cells, and can be used for preparing antitumor drugs.

This invention relates to the preparation of 10-trifluoromethoxycamptothecin compounds and their use in antitumor drugs. The structural formula of these compounds is shown below. In vitro cytotoxicity screening results show that 10-trifluoromethoxycamptothecin compounds possess broad-spectrum antitumor activity, exhibiting strong inhibitory activity against human hepatocellular carcinoma cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human cholangiocarcinoma cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1), and human pancreatic cancer cells (BxPC-3). Compounds 10-trifluoromethoxycamptothecin I and 7-ethyl-10-trifluoromethoxycamptothecin II showed strong inhibitory effects against all seven tested tumor cell lines, with IC50 values ​​exceeding 100%. 50 The concentrations were 0.913–0.0661 μM and 4.932–0.0578 μM, respectively, both significantly superior to the control drug topotecan. Among them, compounds I and II exhibited the strongest inhibitory activity against the BxPC-3 cell line, with IC50 values ​​of [missing value]. 50 The values ​​were 0.0661±0.0065μM and 0.0578±0.0043μM, respectively. Therefore, 10-trifluoromethoxycamptothecin compounds hold promise for development into a novel antitumor drug.

The invention discloses a small molecule peptide with inhibitory activity on breast cancer cells, a preparation and application of the small molecule peptide in treatment of breast cancer, and belongs to the technical field of biomedicine. The amino acid sequence of the small molecule peptide is shown as SEQ ID NO.1. An in-vitro cell experiment proves that the small molecule peptide can remarkably inhibit proliferation of various breast cancer cells and is free of cytotoxicity and good in safety, and the invention further provides a pharmaceutical preparation containing the small molecule peptide. The small molecule peptide and the preparation can significantly inhibit the growth speed of human breast cancer cell MDA-MB-231 transplanted tumor nude mouse tumors, improve the levels of IL-6, IFN-gamma and TNF-alpha cell factors in serum and enhance the immunologic function of nude mice, can be effectively used for breast cancer treatment, provide new candidate drugs and treatment strategies for clinical treatment of breast cancer, and have broad application prospects. Important clinical application values and market prospects are realized.

The invention relates to a phthalazinone compound containing an aryl malonamide structure and application of the phthalazinone compound, and belongs to the technical field of medicines, the phthalazinone compound containing the aryl malonamide structure has a structure shown in a general formula (I), and the phthalazinone compound containing the aryl malonamide structure can be pharmaceutically added with acid to form salt. Pharmacological activity screening results show that the compound has significant inhibition effects on human breast cancer cells MDA-MB-453, human lung adenocarcinoma cells A549 and human colon cancer cells HCT116, and has good prospects in development and application of antitumor drugs.

The application provides a beta'-thio-alpha, beta-unsaturated gamma-lactam derivative and a preparation method and application thereof, and belongs to the technical field of organic chemical synthesis. The beta'-thio-alpha, beta-unsaturated gamma-lactam derivative has a structure shown in formula I. The method constructs a beta'-thio-alpha, beta-unsaturated gamma-lactam derivative molecular skeleton through a free radical coupling and olefin isomerization process under the condition of blue light irradiation with cesium carbonate as an alkali. Through biological activity evaluation, it is found that the beta'-thio-alpha, beta-unsaturated gamma-lactam derivative prepared by the method has an inhibitory effect on MDA-MB-231 human breast cancer cells.

The application provides a sesquiterpene dimer compound, a preparation method and application, and belongs to the field of medical biotechnology. The sesquiterpene dimer compound is extracted and separated from a Lemnalia soft coral to obtain a sesquiterpene dimer compound lemnalinoid L. The sesquiterpene dimer compound lemnalinoid L has an antitumor effect, has inhibitory activity on a human breast cancer cell line MDA-MB-231, can be used for developing a candidate molecule for treating the disease, and can be used as a lead compound for chemical synthesis and structural modification of other drugs. The preparation method is simple and fast, and the extracted new diterpene glycoside compound has high purity.

A multi zonal support structure for a bra cup and a brassiere are disclosed. The cup partition support structure comprises a first supporting part, a second supporting part and a third supporting part. The first supporting part is adapted to conform to a front side and / or an upper side of a human breast, the second supporting part is arranged adjacent to the first supporting part, and the third supporting part is arranged on a side of the second supporting part away from the first supporting part. The first supporting part has a first hardness a, the second supporting part has a second hardness b and the third supporting part has a third hardness c, where a<b<c.

The present invention relates to a method for treating human breast cancers using combination therapy that includes therapeutically effective amounts of an iNOS inhibitor, a PI3K-ATK pathway inhibitor, and ataxane.

The invention discloses a human breast benign and malignant disease body surface scanning detection method and device and a medium, and belongs to the technical field of biomedical instruments. The method comprises the following steps: acquiring depth data and an RGB image of a mammary gland area; planning a scanning path based on the depth data; controlling a mechanical arm to drive an optical fiber Raman probe to scan along the path; acquiring spectral data and preprocessing the spectral data; and synchronously marking the recognition result on the RGB image and displaying the RGB image. A mechanical scanning device is matched with an optical fiber Raman light probe, three-dimensional modeling of a mammary gland area is obtained through the assistance of an active infrared stereoscopic vision technology, a scanning path is automatically planned through an image edge detection algorithm, all-directional, full-automatic and high-sampling-density self-adaptive scanning is carried out on the human mammary gland, and the human mammary gland scanning precision is improved. And the benign and malignant substances of the breast tissue are judged by combining high-precision abnormal Raman spectrum detection and a mode recognition algorithm.

This invention provides a method for the defluorination cyclization reaction of fluoroalkyl peroxides and p-cyanobenzylamine under the promoting conditions of triethylenediamine and potassium phosphate, synthesizing a series of fluoroalkyl pyrrole compounds. This reaction selectively activates the six C(sp) atoms at three carbon sites on the fluoroalkyl chain. 3 By exploiting the F-F bond, the precise synthesis of fluoroalkyl-substituted pyrrole compounds was achieved. This method features mild conditions, good functional group tolerance, simple post-processing, green procedures, low pollution, and high economic benefits. Furthermore, the obtained compounds exhibit certain anti-human breast cancer cell (MDA) activity and can be used to prepare active inhibitors against MDA cells.

This invention discloses a method for preparing selenoyne compounds and their applications. The method involves an addition reaction of benzisoselenopyrone and alkyne, characterized by mild reaction conditions, simple operation, a green solvent, excellent yield, and 100% atom utilization, conforming to click chemistry principles. The obtained selenoyne compounds are easily separated, and their purity is above 98%. The selenoyne compounds provided by this invention exhibit good anti-liver cancer cells, human breast cancer cells, or human non-small cell lung cancer cells, laying the foundation for the screening and development of anticancer drugs. Therefore, this invention has broad application prospects.

The application belongs to the field of medicine, and discloses a compound with the structure of formula I, a preparation method of the compound, and the compound is a pyrazole acylhydrazine derivative containing a diphenyl ether unit, which is obtained by substituting p-chloronitrobenzene with phenol, and then by reduction, diazotization, re-reduction, hydrochloric acid removal and hydrazide reaction; the pyrazole acylhydrazine derivative containing the diphenyl ether unit has obvious inhibitory effect on human pancreatic cancer cells, human breast cancer cells and human gastric cancer cells, and can be used as a potential new type of antitumor candidate drug molecule.

The present application relates to a kind of preparation of new indole camptothecin derivatives and its use in antitumor, the structure of the compound general formula is shown as follows.In vitro cytotoxic activity screening results show that new indole camptothecin derivatives have broad-spectrum antitumor activity, to human hepatoma cell (HepG2), human non-small cell lung cancer cell (A549), human colon cancer cell (SW480), human intrahepatic cholangiocarcinoma cell (RBE), human breast cancer cell (MCF-7), human pancreatic cancer cell (BxPC3), human bladder cancer cell (T24), human bladder cancer cell (umuc3) show strong inhibitory activity. Among them, the antitumor activity of compound D-18 is most outstanding, and shows strong inhibition to the 8 tumor cell lines measured, IC 50 The range is 0.2585-10.69 μM, significantly better than the control drug irinotecan, and comparable to topotecan activity. Therefore, indole camptothecin derivatives are expected to be developed into a new antitumor drug.

The utility model relates to the technical field of mother and baby products, and provides a breast pump with an emulsion output end opening and closing structure, which comprises a main machine, a container, a driver and a three-way assembly with three ends communicated with one another. The first end of the three-way assembly is in butt joint with the human breast, the second end is in butt joint with the air pressure adjusting device, the third end is in butt joint with the container, a switch piece is arranged at the third end of the three-way assembly, and the driver and the switch piece are matched to open and close the third end of the three-way assembly. The opening and closing actions of the switch piece at the third end of the three-way assembly are accurately controlled by the driver, rapid connection and disconnection between the breast pumping channel and the container are achieved, and therefore the negative pressure generation efficiency is optimized.

The application belongs to the technical field of medicines, and particularly relates to 2'-acetyl-2',3'-dihydro-4' H -[cyclohexane-1,1'-isoquinoline]-4'-ketone compounds, a preparation method and uses thereof. The application patent first synthesizes a six-membered spiro ring structure containing an acetyl group, and obtains a novel compound with more antitumor effect. Pharmacological research shows that the compound has certain inhibitory activity on human breast cancer MCF-7 cells.